Interventional, Open-Label, Single Cohort, Canadian Study to Describe the Relationship Between Cognitive Symptoms and Work Productivity in Working Adults Treated With Vortioxetine for Major Depressive Disorder (MDD)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 24 May 2017
At a glance
- Drugs Vortioxetine (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Acronyms AtWoRC
- Sponsors Lundbeck Canada
- 24 May 2017 Results of a primary analysis (n=196), presented at the 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
- 09 Jan 2017 Planned primary completion date changed from 1 Oct 2016 to 1 Aug 2017.
- 12 Jul 2016 Planned End Date changed from 1 Jun 2017 to 1 Aug 2017.